Company intelligence / Profile preview

PhytoMyco Research

Mysuru, Karnataka, Indiaportal.nifa.usda.gov ↗

Ownership: Private
Development stage: Other

Overview

PhytoMyco Research is developing a portfolio of botanically derived drugs and nutraceuticals. Its lead candidate for diabetes is in late-stage development. Other programs target infectious diseases such as tuberculosis and drug-resistant bacteria, with all candidates originating from an extensive natural product library of over 16,000 phytochemicals sourced from indigenous Indian plants. The company leverages traditional medicine knowledge to accelerate development timelines.

Therapeutic areas: ImmunologyEndocrinologyInfectious Diseases
Modalities: Small moleculeNatural product-based drugsBotanically derived products
Industry: Biotech

Drug pipeline

5 assets

PPC 325

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on PhytoMyco Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhytoMyco Research.

Explore the full profile